A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2023-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab
in the treatment of Chinese participants with moderate to severe plaque psoriasis.